Format

Send to

Choose Destination
J Clin Oncol. 2013 Feb 10;31(5):641-6. doi: 10.1200/JCO.2012.47.1227. Epub 2013 Jan 7.

Ethical issues for control-arm patients after revelation of benefits of experimental therapy: a framework modeled in neuroblastoma.

Author information

1
Division of Pediatric Hematology/Oncology, The Herman and Walter Samuelson Children's Hospital at Sinai, 2401 West Belvedere Ave, Baltimore, MD 21215-5271, USA. yunguru@lifebridgehealth.org

Abstract

In 2009, the Children's Oncology Group (COG) phase III randomized controlled trial, ANBL0032, found that adding immunotherapy (Ch14.18) to standard therapy significantly improved outcomes in patients with high-risk neuroblastoma when administered within 110 days after autologous stem-cell transplantation (SCT). After careful deliberation and consultation, the COG Neuroblastoma Committee decided to offer Ch14.18 to prior trial participants who had been randomly assigned to the control arm (no immunotherapy), regardless of the time that had elapsed since SCT. This decision occurred in the context of a limited supply of Ch14.18 and no data regarding its role when administered beyond 110 days. In this article, we analyze the numerous ethical challenges highlighted by the ANBL0032 trial, including the limits of researchers' reciprocity-based obligations to study participants, post-trial access to beneficial therapies, and the balance between scientific knowledge and parental hope. These deliberations may be useful to other researchers when considering their ethical obligations to control-arm participants in the wake of a positive randomized trial.

PMID:
23295797
PMCID:
PMC3565183
DOI:
10.1200/JCO.2012.47.1227
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center